<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77110">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01727245</url>
  </required_header>
  <id_info>
    <org_study_id>2011/1002-31/1</org_study_id>
    <nct_id>NCT01727245</nct_id>
  </id_info>
  <brief_title>NEFA (Non Esterified Fatty Acid) , Adipose Factors Behind Insulin Sensitivity</brief_title>
  <official_title>The Role of Adipose Tissue in Atherogenic Conditions in Man - Mechanisms and Interventions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danderyd Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ersta Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <authority>Sweden: The National Board of Health and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We want to asses the role of adipose tissue for metabolic complications to obesity before
      and after weight loss (surgery).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2011</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Insulin sensitivity, adipose tissue function and gene function</measure>
    <time_frame>two years after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Performed with hyperinsulinemic euglycemic clamp before and two years after surgery. Subcutaneous and visceral fat biopsy at the time of surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>two years after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>DEXA (Dual-Energy X-ray absorptiometry), before and two years after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular function</measure>
    <time_frame>two years after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Non invasive ultrasound of vascular stiffness, before and two years after surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Obesity</condition>
  <condition>Non-obese Controls</condition>
  <arm_group>
    <arm_group_label>Obese</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Obese patients undergoing gastric by-pass surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cholecystectomy and anti-reflux surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Obese</intervention_name>
    <description>gastric bypass</description>
    <arm_group_label>Obese</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control group</intervention_name>
    <description>Cholecystectomy and anti-reflux surgery</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria obese:

          -  Bariatric surgery with laparoscopic gastric by-pass

        Exclusion Criteria obese:

          -  diabetes mellitus typ 2 with insulin treatment and/or glitazones

          -  oral or parenteral steroid treatment

          -  complicated psychiatric disease

          -  Warfarin use

        Inclusion Criteria non-obese controls:

          -  BMI under 30

        Exclusion Criteria non-obese controls:

          -  diabetes

          -  oral or parenteral steroids treatment

          -  complicated psychiatric disease

          -  Warfarins use
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik Näslund, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erik Näslund, Prof.</last_name>
    <phone>+46 8 123 550 17</phone>
    <email>erik.naslund@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mikael Ryden, Ass. Prof</last_name>
    <phone>+46 8 5858 2775</phone>
    <email>mikael.ryden@ki.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Danderyds Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Näslund, Prof.</last_name>
      <phone>+46 8 123550 17</phone>
      <email>erik.naslund@ki.se</email>
    </contact>
    <investigator>
      <last_name>Erik Näslund, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ersta Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>116 91</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Thorell, Ass. Prof.</last_name>
      <phone>+46 8 714 6541</phone>
      <email>anders.thorell@erstadiakoni.se</email>
    </contact>
    <investigator>
      <last_name>Anders Thorell, Ass. Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikael Ryden, Ass. Prof.</last_name>
      <phone>+46 8 5858 2775</phone>
      <email>mikael.ryden@ki.se</email>
    </contact>
    <investigator>
      <last_name>Mikael Ryden, Ass. Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 11, 2014</lastchanged_date>
  <firstreceived_date>November 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Erik Näslund</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
